Trends for 2023: What's coming next in pharma marketing and drug … – Endpoints News

With 2022 almost in the rearview mirror, it’s time to look ahead at what to expect in pharma marketing, advertising and drug commercialization strategies for 2023. This year marked the first full year of widely available Covid-19 vaccines — plus multiple treatments and new boosters — and while no one is suggesting the crisis is over, most agree it is at least moving toward an endemic phase.
Along with that change also comes a pendulum swing back, at least somewhat, toward pre-pandemic pharma practices. Chief among those is a return to in-person sales rep and medical liaison meetings with healthcare professionals.
Unlock this article along with other benefits by subscribing to one of our paid plans.
The Asia Pacific region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilized capacity presenting an opportunity for growth in multinational trials in the region. 
Demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having in Asia Pacific, according to the latest analysis from GlobalData in a new report titled State of the Global Biotech Landscape: Where the Opportunities Lie.
Two biotech leaders are facing the possibility of decades in prison after a federal grand jury in Maryland found them both guilty on multiple charges related to a scheme to defraud investors about the potential of the drug leronlimab, a monoclonal antibody investigational drug also known as PRO 140.
CytoDyn’s former CEO Nader Pourhassan drew attention over the last two years for loudly touting leronlimab as an effective treatment for HIV, cancer and Covid-19, despite clinical data that indicated the opposite.
One of the pioneers of first-gen CAR T has now swooped in to buy a second-gen cell therapy player with some stellar scientific ties, impressive early responses and a clinical record that includes a high-profile blowup in the clinic that killed several patients.
Gilead sub Kite is putting out word today that it’s nailed down the buyout of Tmunity, a cell therapy spinout out of Penn that was derailed by lethal toxicity.
Unlock this article along with other benefits by subscribing to one of our paid plans.
Roche let the air out of the TIGIT party balloon with a pair of crushing Phase III failures. Now Gilead $GILD and Arcus $RCUS are back with details of their closely-watched Phase II data in Stage IV non-small cell lung cancer, hoping to spark some renewed enthusiasm for their contender and the rest of the field.
But despite some positive results in frontline therapy for patients with high PD-L1 levels, plus a claim on a potential “new standard of care,” the mid-stage readout from the ARC-7 study won’t end the running debate that has blighted expectations for the target.
Unlock this article along with other benefits by subscribing to one of our paid plans.
As the flu season continues to rage, with the CDC reporting over 23,000 hospitalizations for influenza, several manufacturers have reported shortages of a medicine that can be used to counter it.
The American Society of Health-System Pharmacists (ASHP) reported a shortage of oseltamivir, otherwise known as Tamiflu, in several doses by five generic manufacturers. Amneal and Camber have reported a shortage in the 30 mg, 45 mg and 75 mg doses, while Macleods is reporting a shortage only in the 30 mg and 75 mg amounts. Teva and Zydus are listing a shortage of oral powder in the 60 mL bottle amount.
Real Chemistry is fighting hate speech this holiday season with the help of a browser extension that replaces offensive language with heart-healthy cooking recipes.
The project is part of the healthcare company’s annual holiday campaign, delivered to clients’ inboxes in the form of a greeting card. Last season, the team remade the classic Christmas song “Carol of the Bells” using recordings of cheers for healthcare workers during the pandemic.
Novartis is ringing in the new year with more job cuts, according to New Jersey state documents.
The pharma giant is axing 284 jobs in East Hanover, a township about 24 miles away from New York City. The cuts, which span Novartis Services, Novartis Pharmaceuticals and Novartis Corporation, take effect on Jan. 28, according to a notice posted last month in New Jersey’s state Worker Adjustment and Retraining Notification Act (WARN) system.
Aduhelm’s successor is now weeks away from its PDUFA date — and several advocacy groups are arguing for the reversal of a controversial CMS policy.
The groups, including the Azheimer’s Association and a number of doctors and medical professionals, are advocating for CMS to reconsider its January announcement that restricts the reimbursement of Aduhelm and other anti-amyloid monoclonal antibodies for Alzheimer’s disease to patients enrolled in CMS-approved, randomized controlled trials.
After committing about $2 billion for new biomanufacturing efforts, next year’s $1.7 trillion government spending bill features new pharma manufacturing efforts.
In addition to creating National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing, and providing $10 million for unannounced foreign inspection pilot, other provisions will seek to mitigate drug shortages that have hit several high-profile drugs recently.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source

Leave a Comment

%d bloggers like this: